Mirapexin (Pramipexole Dihydrochloride Monohydrate)

Pramipexole, the active ingredient in Mirapexin, is a dopamine agonist presented as a tablet for oral use. It treats Parkinson's disease and restless legs syndrome in adults.

GNH USA supplies Mirapexin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pramipexole is a dopamine agonist used in movement‑disorder therapy.

- Parkinson's disease: improves motor symptoms and reduces OFF periods. - Restless legs syndrome: alleviates uncomfortable sensations and reduces the urge to move. - Adjunct therapy in Parkinson's disease: enhances motor control when combined with levodopa.

Pramipexole may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: sensation of light‑headedness, especially on standing. - Somnolence: increased sleepiness or fatigue. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Hallucinations: visual or auditory disturbances. - Impulse control disorders: compulsive gambling, shopping or eating. - Sudden onset of sleep: unexpected episodes of falling asleep.

Before prescribing Mirapexin, clinicians should consider several safety measures.

- Psychiatric monitoring: watch for hallucinations, depression, or suicidal thoughts. - Renal function assessment: dose may need adjustment in impaired kidneys. - Elderly patients: start with the lowest effective dose and titrate slowly. - Discontinuation: avoid abrupt cessation to reduce withdrawal symptoms. - Driving caution: advise patients about possible somnolence and dizziness. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Pramipexole can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): may antagonize pramipexole’s dopaminergic effect. - MAO‑B inhibitors (e.g., selegiline): increase risk of hypertensive episodes. - Alcohol: can potentiate central nervous system depression.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive orthostatic hypotension may occur. - CNS depressants (e.g., benzodiazepines, opioids): enhanced sedation. - SSRIs or SNRIs: monitor for mood changes or rare serotonin‑related effects.